CCM
ATRA icon

Consonance Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Consonance Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-66,772
Closed -$24M – 34
2021
Q1 		$24M Sell
66,772
-74,538
-53% -$32.9M 2.56% 17
2020
Q4 		$69.3M Sell
141,310
-46,111
-25% -$21.3M 6.48% 5
2020
Q3 		$60.7M Sell
187,421
-22,108
-11% -$7.53M 7.4% 4
2020
Q2 		$76.3M Buy
+209,529
New +$52.9M 4.57% 10

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Consonance Capital Management's ATRA Position: Q2 2021 in Review

Consonance Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 66,772 shares — an estimated $24M sold.

Consonance Capital Management first reported a position in ATRA in Q2 2020 and held it in 4 quarters. The position peaked at $76.3M in Q2 2020. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

  • Consonance Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Consonance Capital Management sold 66,772 Atara Biotherapeutics shares in Q2 2021, an estimated $24M.
  • Consonance Capital Management first reported a position in Atara Biotherapeutics in Q2 2020 and held it in 4 quarters.
  • Consonance Capital Management's Atara Biotherapeutics position peaked at $76.3M in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Consonance Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.